These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 26816909)

  • 1. Efficacy, Safety and Treatment Satisfaction of Glimepiride vs Sitagliptin in Combination with Metformin in Type 2 Diabetes Mellitus.
    Kumar S; Pathak AK; Saikia D; Kumar A
    J Clin Diagn Res; 2015 Dec; 9(12):FC07-10. PubMed ID: 26816909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Evaluation of Safety and Efficacy of Glimepiride and Sitagliptin in Combination with Metformin in Patients with Type 2 Diabetes Mellitus: Indian Multicentric Randomized Trial - START Study.
    Devarajan TV; Venkataraman S; Kandasamy N; Oomman A; Boorugu HK; Karuppiah SKP; Balat D
    Indian J Endocrinol Metab; 2017; 21(5):745-750. PubMed ID: 28989886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
    Srivastava S; Saxena GN; Keshwani P; Gupta R
    J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
    Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of sitagliptin when added to ongoing therapy in korean subjects with type 2 diabetes mellitus.
    Chung HS; Lee MK
    Diabetes Metab J; 2011 Aug; 35(4):411-7. PubMed ID: 21977462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sitagliptin 100 mg vs glimepiride 1-3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM).
    Kesavadev J; Pillai PBS; Shankar A; Krishnan G; Jothydev S
    Endocr Connect; 2017 Nov; 6(8):748-757. PubMed ID: 28982699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Slope of change in HbA
    DeFronzo RA; Ferrannini E; Schernthaner G; Hantel S; Elsasser U; Lee C; Hach T; Lund SS
    Endocrinol Diabetes Metab; 2018 Apr; 1(2):e00016. PubMed ID: 30815552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal candidates for the switch from glimepiride to sitagliptin to reduce hypoglycemia in patients with type 2 diabetes mellitus.
    Kim HM; Lim JS; Lee BW; Kang ES; Lee HC; Cha BS
    Endocrinol Metab (Seoul); 2015 Mar; 30(1):84-91. PubMed ID: 25325279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Luis Bautista J; Bugos C; Dirnberger G; Atherton T
    Clin Ther; 2003 Jan; 25(1):194-209. PubMed ID: 12637120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy of sitagliptin and glimepiride dose-up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination.
    Shimoda S; Iwashita S; Sekigami T; Furukawa N; Matsuo Y; Ichimori S; Goto R; Maeda T; Watanabe E; Kondo T; Matsumura T; Motoshima H; Nishida K; Araki E
    J Diabetes Investig; 2014 May; 5(3):320-6. PubMed ID: 24843781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors of durability to sitagliptin: Slower reduction of glycated hemoglobin, older age and higher baseline glycated hemoglobin.
    Chung HS; Suh S; Kim MY; Kim SK; Kim HK; Lee JI; Hur KY; Kim JH; Min YK; Lee MS; Kim KW; Kim SW; Chung JH; Lee MK
    J Diabetes Investig; 2014 Feb; 5(1):51-9. PubMed ID: 24843737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
    Peng XV; Marcinak JF; Raanan MG; Cao C
    Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial.
    Kondo Y; Harada N; Hamasaki A; Kaneko S; Yasuda K; Ogawa E; Harashima S; Yoneda H; Fujita Y; Kitano N; Nakamura Y; Matsuo F; Shinji M; Hinotsu S; Nakayama T; Inagaki N;
    Diabetol Metab Syndr; 2016; 8():15. PubMed ID: 26925169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of sitagliptin and glimepiride on C-reactive protein (CRP) in overweight Type-2 diabetic patients.
    Hussain M; Rafique MA; Iqbal J; Akhtar L
    Pak J Med Sci; 2019; 35(2):383-387. PubMed ID: 31086519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.
    Pérez-Monteverde A; Seck T; Xu L; Lee MA; Sisk CM; Williams-Herman DE; Engel SS; Kaufman KD; Goldstein BJ
    Int J Clin Pract; 2011 Sep; 65(9):930-8. PubMed ID: 21849007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety of initial treatment with glimpeiride versus sitagliptin in type 2 diabetes].
    Tamez-Pérez HE;
    Rev Med Inst Mex Seguro Soc; 2015; 53(2):142-8. PubMed ID: 25760742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.